Have a personal or library account? Click to login
National and Subnational Burden of Cardiovascular Diseases in Iran from 1990 to 2021: Results from Global Burden of Diseases 2021 study Cover

National and Subnational Burden of Cardiovascular Diseases in Iran from 1990 to 2021: Results from Global Burden of Diseases 2021 study

Global Heart
Volume 20 (2025): Issue 1
By: Mahsa Heidari-Foroozan,  Melina Farshbafnadi,  Ali Golestani,  Sepehr Younesian,  Hosein Jafary,  Mohammad-Mahdi Rashidi,  Ozra Tabatabaei-Malazy,  Nazila Rezaei,  Mostafa Moghimi Kheirabady,  Arash Bagherian Ghotbi and  Seyyed-Hadi Ghamari  
Open Access
|May 2025

References

  1. 1Tasavon Gholamhoseini M, Arjomand Kermani S, Yazdi-Feyzabadi V, Goudarzi R. Economic burden of cardiovascular diseases among elderly patients in Iran: A case from a developing country. BMC Health Services Research. 2024;24(1):1355. DOI: 10.1186/s12913-024-11808-0
    Back to article
  2. 2Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors: 2020 and beyond. Journal of the American College of Cardiology. 2019;74(20):2529–2532. DOI: 10.1016/j.jacc.2019.10.009
    Back to article
  3. 3Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. The Lancet. 2012;380(9859):2095–128. DOI: 10.1016/S0140-6736(12)61728-0
    Back to article
  4. 4Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): A prospective cohort study. The Lancet. 2020;395(10226):795–808. DOI: 10.1016/S0140-6736(19)32008-2
    Back to article
  5. 5Bloom DE, Chisholm D, Jané-Llopis E, Prettner K, Stein A, Feigl A. From burden to “Best Buys”: Reducing the economic impact of non-communicable diseases. Geneva, Switzerland: World Health Organization; 2011.
    Back to article
  6. 6Emamgholipour S, Sari AA, Pakdaman M, Geravandi S. Economic burden of cardiovascular disease in south west of Iran. International Cardiovascular Research Journal. 2018;12(1).
    Back to article
  7. 7Mokhtari M, Khalil D, Farzadfar F, Daroudi R, Asadi-Lari M. The Burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of IraPEN program in the general population of Iran. Med J Islam Repub Iran. 2022;36:73. DOI: 10.47176/mjiri.36.73
    Back to article
  8. 8Mawdoodi S, Khadem-rezaiyan M, Belyani S, Alinezhad-Namaghi M. The cardiovascular mortality risk factors in the Northeast of Iran: A four-year cohort study. Journal of Nutrition, Fasting and Health. 2023;11(2):104–12.
    Back to article
  9. 9Koolaji S, Sharifnejad Tehrani Y, Azadnajafabad S, Saeedi Moghaddam S, Shahin S, Ghamari A, et al. A 30-year trend of ischemic heart disease burden in a developing country; a systematic analysis of the global burden of disease study 2019 in Iran. Int J Cardiol. 2023;379:127–33. DOI: 10.1016/j.ijcard.2023.03.012
    Back to article
  10. 10Zangeneh A, Najafi F, Khosravi A, Ziapour A, Molavi H, Moradi Z, et al. Epidemiological patterns and spatiotemporal analysis of cardiovascular disease mortality in Iran: Development of public health strategies and policies. Current Problems in Cardiology. 2024;49(8):102675. DOI: 10.1016/j.cpcardiol.2024.102675
    Back to article
  11. 11Brauer M, Roth GA, Aravkin AY, Zheng P, Abate KH, Abate YH, et al. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2162–203. DOI: 10.1016/S0140-6736(24)00933-4
    Back to article
  12. 12Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2133–61. DOI: 10.1016/S0140-6736(24)00757-8
    Back to article
  13. 13Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet. 2024;403(10440):2100–32. DOI: 10.1016/S0140-6736(24)00367-2
    Back to article
  14. 14Stevens GA, Alkema L, Black RE, Boerma JT, Collins GS, Ezzati M, et al. Guidelines for accurate and transparent health estimates reporting: The GATHER statement. The Lancet. 2016;388(10062):e19–e23. DOI: 10.1016/S0140-6736(16)30388-9
    Back to article
  15. 15Mensah GA, Fuster V, Murray CJ, Roth GA, GBoC Diseases, Risk Collaborators. Global burden of cardiovascular diseases and risks, 1990–2022. Journal of the American College of Cardiology. 2023;82(25):2350–473. DOI: 10.1016/j.jacc.2023.11.007
    Back to article
  16. 16Azadnajafabad S, Saeedi Moghaddam S, Mohammadi E, Rezaei N, Rashidi MM, Rezaei N, et al. Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Frontiers in Oncology. 2023;13:1132816. DOI: 10.3389/fonc.2023.1132816
    Back to article
  17. 17Heidari-Foroozan M, Saeedi Moghaddam S, Keykhaei M, Shobeiri P, Azadnajafabad S, Esfahani Z, et al. Regional and national burden of leukemia and its attributable burden to risk factors in 21 countries and territories of North Africa and Middle East, 1990–2019: Results from the GBD study 2019. J Cancer Res Clin Oncol. 2023;149(8):4149–61. DOI: 10.1007/s00432-022-04293-7
    Back to article
  18. 18Murray CJ, Abbafati C, Abbas KM, Abbasi M, Abbasi-Kangevari M, Abd-Allah F, et al. Five insights from the global burden of disease study 2019. The Lancet. 2020;396(10258):1135–59. DOI: 10.1016/S0140-6736(20)31404-5
    Back to article
  19. 19Rostami R, Moradinazar M, Moradi S, Samannejad B, Cheshmeh S, Saber A, et al. Impact of dietary risk on global ischemic heart disease: findings from 1990–2019. Scientific Reports. 2024;14(1):18012. DOI: 10.1038/s41598-024-69089-w
    Back to article
  20. 20Vervoort D, Pezzella AT. Global cardiac surgery and the global burden of disease. In Kpodonu J (Ed.) Global Cardiac Surgery Capacity Development in Low and Middle Income Countries. Switzerland; 2022. pp. 101–6. DOI: 10.1007/978-3-030-83864-5_8
    Back to article
  21. 21Lababidi H, Salerno PRVO, Wass SY, Shafiabadi Hasani N, Bourges-Sevenier B, Al-Kindi S. The Global burden of premature cardiovascular disease, 1990–2019. International Journal of Cardiology Cardiovascular Risk and Prevention. 2023;19:200212. DOI: 10.1016/j.ijcrp.2023.200212
    Back to article
  22. 22Kpodonu J. Global cardiac surgery capacity development in low and middle income countries: Springer; 2022. DOI: 10.1007/978-3-030-83864-5
    Back to article
  23. 23Geldsetzer P, Manne-Goehler J, Marcus M-E, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1 1 million adults. The Lancet. 2019;394(10199):652–62. DOI: 10.1016/S0140-6736(19)30955-9
    Back to article
  24. 24Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med. 2020;7:544302. DOI: 10.3389/fcvm.2020.544302
    Back to article
  25. 25Kuzan A, Królewicz E, Kustrzeba-Wójcicka I, Lindner-Pawłowicz K, Sobieszczańska M. How diabetes and other comorbidities of elderly patients and their treatment influence levels of glycation products. Int J Environ Res Public Health. 2022;19(12). DOI: 10.3390/ijerph19127524
    Back to article
  26. 26Conte M, Petraglia L, Poggio P, Valerio V, Cabaro S, Campana P, et al. Inflammation and cardiovascular diseases in the elderly: The role of epicardial adipose tissue. Front Med (Lausanne). 2022;9:844266. DOI: 10.3389/fmed.2022.844266
    Back to article
  27. 27Sarraf-Zadegan N, Boshtam M, Malekafzali H, Bashardoost N, Sayed-Tabatabaei FA, Rafiei M, et al. Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. Acta Cardiol. 1999;54(6):327–33.
    Back to article
  28. 28Jafary H, Shabanian M, Heidari-Foroozan M, Rashidi MM, Mousavi SM, Golestani A, et al. Sex disparity in non-communicable disease burden in Iran from 1990 to 2021 based on the global burden of disease study. Sci Rep. 2025;15(1):9969. DOI: 10.1038/s41598-025-94015-z
    Back to article
  29. 29Stanhewicz AE, Wenner MM, Stachenfeld NS. Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan. Am J Physiol Heart Circ Physiol. 2018;315(6):H1569–h88. DOI: 10.1152/ajpheart.00396.2018
    Back to article
  30. 30Xiang D, Liu Y, Zhou S, Zhou E, Wang Y. Protective effects of estrogen on cardiovascular disease mediated by oxidative stress. oxid med cell longev. 2021;2021:5523516. DOI: 10.1155/2021/5523516
    Back to article
  31. 31Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women’s cardiovascular health: Is it really an obvious relationship? Arch Med Sci. 2023;19(2):458–66. DOI: 10.5114/aoms/157308
    Back to article
  32. 32Amerzadeh M, Takian A. Reducing sugar, fat, and salt for prevention and control of noncommunicable diseases (NCDs) as an adopted health policy in Iran. Med J Islam Repub Iran. 2020;34:136. DOI: 10.47176/mjiri.34.136
    Back to article
  33. 33Peymani P, Joulaie H, Zamiri N, Ahmadi SM, Dinarvand R, Hosseini H, et al. Iran’s experience on reduction of trans-fatty acid content in edible oils. Middle East J Sci Res. 2012;11(9):1207–11.
    Back to article
  34. 34Kheirandish M, Asgari S, Lotfaliany M, Bozorgmanesh M, Saadat N, Tohidi M, et al. Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid and glucose study. Lipids in health and disease. 2014;13:1–13. DOI: 10.1186/1476-511X-13-20
    Back to article
  35. 35Mousavi SM, Sadeghifar J. Universal health coverage in Iran. The lancet global health. 2016;4(5):e305–e6. DOI: 10.1016/S2214-109X(16)00068-1
    Back to article
  36. 36Tavassoli M. Iranian health houses open the door to primary care. Bulletin of the World Health Organization. World Health Organization. 2008;86(8). DOI: 10.2471/BLT.08.030808
    Back to article
  37. 37Oori MJ, Mohammadi F, Norozi K, Fallahi-Khoshknab M, Ebadi A, Gheshlagh RG. Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004–2018. Curr Hypertens Rev. 2019;15(2):113–22. DOI: 10.2174/1573402115666190118142818
    Back to article
  38. 38Heidari-Foroozan M, Rezaei N, Malekpour M-R, Behnoush AH, Ahmadi N, Abbasi-Kangevari M, et al. Hypertension prevalence and cascade of care in Iran: Updates from the STEPs 2021 national and subnational survey. ResearchGate [preprint]. 2024 [cited December 2024, Page 4–5]. Available from: https://www.researchsquare.com/article/rs-3842876/v1
    Back to article
  39. 39Shams M, Pariani A, Raeisi A, Maleki M, Shariatinia S, Jamalizadeh A, et al. The Iranian national blood pressure measurement campaign: What do the process and output evaluation say? Arch Iran Med. 2022;25(11):718–24. DOI: 10.34172/aim.2022.113
    Back to article
  40. 40Schwingshackl L, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, Andriolo V, et al. Food groups and risk of hypertension: A systematic review and dose-response meta-analysis of prospective studies. Adv Nutr. 2017;8(6):793–803. DOI: 10.3945/an.117.017178
    Back to article
DOI: https://doi.org/10.5334/gh.1429 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Dec 30, 2024
Accepted on: May 7, 2025
Published on: May 16, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Cardiovascular Diseases,
GBD,
Epidemiology,
Embolism,
Iran,
Myocardial Ischemia

© 2025 Mahsa Heidari-Foroozan, Melina Farshbafnadi, Ali Golestani, Sepehr Younesian, Hosein Jafary, Mohammad-Mahdi Rashidi, Ozra Tabatabaei-Malazy, Nazila Rezaei, Mostafa Moghimi Kheirabady, Arash Bagherian Ghotbi, Seyyed-Hadi Ghamari, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 20 (2025): Issue 1Next article